

Lesson 4 in Lung Cancer and Medicine | Beyond Treatment: Wellbeing and the Future of Lung Cancer Care

Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017).

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. *JAMA*, 318(2), 197–198.

<https://doi.org/10.1001/jama.2017.7156>

Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021). Evolution

of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. *Nature*

reviews. Clinical oncology, 18(9), 547–557. <https://doi.org/10.1038/s41571-021-00501-4>

Lim, Z. F., & Ma, P. C. (2019). Emerging insights of tumor heterogeneity and drug resistance

mechanisms in lung cancer targeted therapy. *Journal of hematology & oncology*, 12(1),

134. <https://doi.org/10.1186/s13045-019-0818-2>

Mitsudomi, T., Suda, K., & Yatabe, Y. (2013). Surgery for NSCLC in the era of personalized

medicine. *Nature reviews. Clinical oncology*, 10(4), 235–244.

<https://doi.org/10.1038/nrclinonc.2013.22>

Neal, J. W. & Diehn, M. (2025). Adjuvant ctDNA-Adapted Personalized Treatment in Early

Stage NSCLC (ADAPT-E). *ClinicalTrials*, Stanford University, NCT04585477.

<https://clinicaltrials.gov/study/NCT04585477>

Noonberg, S. B., & Benz, C. C. (2000). Tyrosine kinase inhibitors targeted to the epidermal

growth factor receptor subfamily: role as anticancer agents. *Drugs*, 59(4), 753–767.

<https://doi.org/10.2165/00003495-200059040-00003>

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-Related Adverse Events

Associated with Immune Checkpoint Blockade. *The New England journal of medicine*, 378(2), 158–168. <https://doi.org/10.1056/NEJMra1703481>

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., Brahmer, J. R., & KEYNOTE-024 Investigators (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *The New England journal of medicine*, 375(19), 1823–1833. <https://doi.org/10.1056/NEJMoa1606774>

Shepherd, F. A., Pereira, J., Ciuleanu, T. E., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarabara, P., & Seymour, L. (2004). A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 22(14). <https://doi.org/10.1200/jco.2004.22.90140.7022>

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabárbara, P., Seymour, L., & National Cancer Institute of Canada Clinical Trials Group (2005). Erlotinib in previously treated non-small-cell lung cancer. *The New England journal of medicine*, 353(2), 123–132. <https://doi.org/10.1056/NEJMoa050753>

Shi, Y., Au, J. S., Thongprasert, S., Srinivasan, S., Tsai, C. M., Khoa, M. T., Heeroma, K., Itoh,

- Y., Cornelio, G., & Yang, P. C. (2014). A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 9(2), 154–162.
<https://doi.org/10.1097/JTO.0000000000000033>
- Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., Lee, S. M., ... FLAURA Investigators (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *The New England journal of medicine*, 378(2), 113–125.
<https://doi.org/10.1056/NEJMoa1713137>
- Spratt, D. E., Tang, S., Sun, Y., Huang, H. C., Chen, E., Mohamad, O., Armstrong, A. J., Tward, J. D., Nguyen, P. L., Lang, J. M., Zhang, J., Mitani, A., Simko, J. P., DeVries, S., van der Wal, D., Pinckaers, H., Monson, J. M., Campbell, H. A., Wallace, J., Ferguson, M. J., ... Feng, F. Y. (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. *NEJM evidence*, 2(8), EVIDoa2300023.
<https://doi.org/10.1056/EVIDoa2300023>
- Yang, C. Y., Yang, J. C., & Yang, P. C. (2020). Precision Management of Advanced Non-Small Cell Lung Cancer. *Annual review of medicine*, 71, 117–136.
<https://doi.org/10.1146/annurev-med-051718-013524>